Phase 2 N=296 Therapy for Pediatric Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=23 Massage for Pediatric Oncology
Bone Marrow Transplantation · Distress
Primary: Number of Days With Pain Scores >3 Measured on Numeric Rating Scale (Range 0-10; 0 for no Pain; 10 for Worst Pain Imaginable) — 7.7; 8.3 days — p=0.80
Phase 2 N=72 A Study of Pemetrexed in Children With Recurrent Cancer
Osteosarcoma · Medulloblastoma · Sarcoma, Ewing's
Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants
Phase 2 N=80 Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Hodgkin's Lymphoma
Primary: 3-year Event-Free Survival Probability — 0.887 probability — p=0.9970
N/A N=445 Symptom Screening Linked to Care Pathways
Pediatric Cancer · Quality of Life
Primary: Symptom Screening in Pediatrics Tool (SSPedi) Total Score — 7.9; 11.4 Score on a scale
Phase 1 N=68 A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Neoplasm Metastasis
Primary: Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants
Phase 2 N=64 Therapy for Children With Advanced Stage Neuroblastoma
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Phase 1 N=8 Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
Phase 2 N=38 NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia
Leukemia, Lymphocytic, Acute
Primary: Toxicity of Treatment in Terms of Number of Participants With Serious Adverse Events or Adverse Events, Reported — 26 Participants
Phase 2 N=57 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Solid Tumours
Primary: Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Primary Interest (RMS, NRSTS or Ewing Sarcoma/pPNET) — 8.3; 0.0; 0.0…
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
N/A N=70 Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Non-rhabdomyosarcoma Soft Tissue Sarcoma · Bone Sarcoma
Primary: Cumulative Incidence (Estimated Percentage of Participants) Who Developed Toxicities Following Radiation Treatment — 17.7 percentage of participants
N/A N=610 Home Away From Home - Medical Outcomes
Acute Myeloid Leukemia · Neutropenia · Bacteremia
Primary: Occurrence of Post-chemotherapy Bacteremia — 22; 81 Participants
Phase 2 N=100 Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
Brain Tumor · Low Grade Glioma · Astrocytoma
Primary: Endocrine Dysfunction — 14.5; 20.2 percentage of participants
Phase 2 N=47 Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
Acute Leukaemia · Chronic Disease · Leukemia
Primary: Number of High Risk Pediatric Patients With Successful Sustained Donor Engraftments — 16; 18; 10 participants
Phase 2 N=13 Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors
Childhood CNS Primitive Neuroectodermal Tumor
Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants
N/A N=14 Stereotactic Radiation Therapy for Pediatric Sarcomas
Sarcoma · Metastatic Disease · Bony Sites
Primary: Lesion-specific Local Control at 6 Months Post-SBRT as Assessed by Percentage of Lesions Locally Controlled — 95 percentage of lesions
Phase 2 N=32 A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
Phase 2 N=40 Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia · Lymphoma, Lymphoblastic
Primary: Response Rate — 0.846; 0.786; 0.154; 0.214 proportion of participants
Phase 2 N=106 Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Leukemia, Pediatric
Primary: 3-year Event-free Survival (EFS) Rate — 66.0 Percentage of Participants — p=0.032
N/A N=52 Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
Neuroblastoma · Medulloblastoma · Brain Tumors
Primary: Determine Feasibility Using Days From the Date of Biopsy to Date of Start of Treatment — 12.2; 19.9; 14.9 Days
Phase 1 N=7 HUMC 1612: Optune NovoTTF-200A System
High Grade Glioma · Ependymoma
Primary: Safety of the Optune NovoTTF-200A System When Used Alone in Pediatric Patients With Recurrent High-grade Gliomas. — 0 Participants
Phase 3 N=91 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35
Phase 2 N=42 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Phase 2 N=34 Antineoplaston Therapy in Treating Children With Brain Tumors
Childhood Brain Tumors
Primary: Number of Participants With Objective Response — 1; 5; 6; 18 Participants
N/A N=115 Proton Radiation Therapy (RT) for the Treatment of Pediatric Rhabdomyosarcoma
Rhabdomyosarcoma
Primary: Cumulative Incidence (Estimated Percent of Participants) With Grade 3 or Higher Toxicity in Follow-up — 10.9 Percentage of patients
Phase 2 N=51 Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma
Hypertension · Osteonecrosis · Osteonecrosis Due to Drug
Primary: Extensive Radiographic Osteonecrosis — 20; 21; 1; 2 Participants — p=0.7139
Phase 2 N=12 Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
Low-grade Glioma
Primary: Progression-free Survival — 23.1 percentage
Phase 2 N=53 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
N/A N=40 Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention
Other Cancer
Primary: Percentage of Participants Recruited — 20; 20 Participants